Brazil's R&D-based industry outlines priorities for new president
This article was originally published in SRA
Executive Summary
With Brazil's new president, Dilma Rousseff, to be inaugurated in January, the pharmaceutical industry has a list of issues that it would like the government to tackle. Greater pricing freedom and reducing the time it takes to grant a patent are just two priorities, explains Jorge Raimundo, president of the advisory council of Interfarma, Brazil's R&D-based industry association1.